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Abstract 
Background: Multiple autoimmune syndrome (MAS), an extreme phenotype of autoimmune disorders, is a very well 
suited trait to tackle genomic variants of these conditions. Whole exome sequencing (WES) is a widely used strategy 
for detection of protein coding and splicing variants associated with inherited diseases.
Methods: The DNA of eight patients affected by MAS [all of whom presenting with Sjögren’s syndrome (SS)], four 
patients affected by SS alone and 38 unaffected individuals, were subject to WES. Filters to identify novel and rare 
functional (pathogenic–deleterious) homozygous and/or compound heterozygous variants in these patients and 
controls were applied. Bioinformatics tools such as the Human gene connectome as well as pathway and network 
analysis were applied to test overrepresentation of genes harbouring these variants in critical pathways and networks 
involved in autoimmunity.
Results: Eleven novel and rare functional variants were identified in cases but not in controls, harboured in: MACF1, 
KIAA0754, DUSP12, ICA1, CELA1, LRP1/STAT6, GRIN3B, ANKLE1, TMEM161A, and FKRP. These were subsequently subject 
to network analysis and their functional relatedness to genes already associated with autoimmunity was evaluated. 
Notably, the LRP1/STAT6 novel mutation was homozygous in one MAS affected patient and heterozygous in another. 
LRP1/STAT6 disclosed the strongest plausibility for autoimmunity. LRP1/STAT6 are involved in extracellular and intracel‑
lular anti‑inflammatory pathways that play key roles in maintaining the homeostasis of the immune system. Further; 
networks, pathways, and interaction analyses showed that LRP1 is functionally related to the HLA‑B and IL10 genes 
and it has a substantial impact within immunological pathways and/or reaction to bacterial and other foreign proteins 
(phagocytosis, regulation of phospholipase A2 activity, negative regulation of apoptosis and response to lipopolysac‑
charides). Further, ICA1 and STAT6 were also closely related to AIRE and IRF5, two very well known autoimmunity genes.
Conclusions: Novel and rare exonic mutations that may account for autoimmunity were identified. Among those, 
the LRP1/STAT6 novel mutation has the strongest case for being categorised as potentially causative of MAS given the 
presence of intriguing patterns of functional interaction with other major genes shaping autoimmunity.
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Background
Recent evidence supports the involvement of rare vari-
ants (population allele frequency <1%) in the aetiology 
of common diseases [1, 2]. It is possible that much of the 
genetic control of common diseases is due to rare and 
pathogenic variants with a major effect on the phenotype. 
The detection of these rare genomic variants harboured 
in coding regions has shown to be achievable using 
extreme phenotypes (those exhibiting an unexpected and 
extreme accumulation of signs and/or symptoms than 
those expected by the disease’s natural history) and pedi-
grees segregating exceptional phenotypes [1, 2].
Polyautoimmunity is defined as the presence of more 
than one autoimmune disease (AD) in a single patient 
[3]. When three or more ADs coexist, the condition is 
called multiple autoimmune syndrome (MAS), which 
characterises the best example of polyautoimmunity, 
and probably the most conspicuous extreme autoim-
mune phenotype [4] i.e., (1) MAS amalgamates signs and 
symptoms that are present in several ADs, (2) the MAS 
signs and symptoms clustering is not random but it out-
lines the presence of subtypes, (3) in many occurrences, 
it clusters in families, and (4) major gene effects and the 
potential location of these MAS major loci have been 
established [4, 5]. Consequently, it is fair to consider that 
MAS, as an extreme phenotype of autoimmunity, would 
be critical for dissecting genes of major effect confer-
ring susceptibility to autoimmunity [5, 6]. Sjögren’s syn-
drome (SS), an autoimmune exocrinopathy, is frequently 
observed in MAS patients [7].
Whole exome sequencing (WES) is a cost effective 
technique, becoming the first-line approach for mono-
genic disorders, and an alternative one for dissecting 
extreme phenotypes of complex inherited conditions 
[5]. WES is a highly effective approach for identifying 
homozygous, compound heterozygous, novel, germinal, 
and de novo rare coding variants [5]. Its ultimate ration-
ale remains in that genetic variants located in exons are 
more likely to be pathogenic, with major effect than many 
of those located in introns or between genes. The power 
of this strategy has increased with available access to 
large numbers of publicly available exome sequence data-
bases that allow the controlled comparison of frequen-
cies, as well as the identification of de novo variants and 
stratification by ethnicity. In this manuscript we report 
the identification of rare and novel variants observed in 
sporadic MAS and SS patients.
Methods
Patients and controls
Eight patients with MAS and four patients with SS alone, 
fulfilling validated classification criteria as previously 
reported [3, 4, 8] were included. Patients were assessed at 
the Center for Autoimmune Diseases Research (CREA), 
at the University of Rosario, in Bogotá and Medellin, 
Colombia (Table  1). Patients and controls did not pre-
sent cardiovascular disease (i.e., ischemic heart disease or 
stroke), or diabetes.
DNA library preparation, exome capture and sequencing 
protocol
Libraries were constructed from 1 μg of genomic DNA 
using an Illumina TruSeq genomic DNA library kit at 
the Biomolecular Resource Facility, John Curtin School 
of Medical Research. Libraries were multiplexed with 
six samples pooled together (500  ng of each library). 
Exons were enriched from the pooled 3  μg of library 
DNA using the Nimblegen Exome enrichment kit. Each 
exome-enriched pool was run on a 100-base-pair paired 
and run on an Illumina HiSeq 2000 sequencer.
Sequence read processing, alignment, bioinformatics, 
and genetic analyses
The sequencing image data was converted to FASTQ files 
containing DNA base calls (A, C, G and T) and quality 
scores using the Illumina CASAVA pipeline in order to 
convert raw image data into sequences. The resulting 
FASTQ files were further processed for variant analysis.
The workflow for data curation and analysis for vari-
ant calling was developed by the Genome Discovery 
Unit, at the Australian National University. Key compo-
nents of the workflow include: (1) quality assessment; 
(2) read alignment; (3) local realignment around the 
known and novel insertions/deletions (indel) regions to 
refine indel boundaries; (4) recalibration of base quali-
ties; (5) variant calling using the Genome Alignment 
Table 1 Phenotypic information for individuals carrying a 
MAS or Sjögren’s phenotype
AITD autoimmune thyroid disease, SLE systemic lupus erythematous, SS 
Sjögren’s syndrome, SSc systemic sclerosis, RA rheumatoid arthritis, VIT vitiligo, 
PSO psoriasis, AIH autoimmune hepatitis.
Patient ID Phenotype Gender Age of onset
1 MAS (SS, AITD, VIT) F 45
2 MAS (SS, SSc, AIH, AITD) F 67
3 MAS (RA, SS, AITD) F 43
4 MAS (PSO, RA, SS) F 48
5 MAS (AITD, RA, SS) F 47
6 MAS (AITD, RA, SS) F 54
7 MAS (SLE, SS, AITD) F 28
8 MAS (RA, SLE, SS) F 36
9 SS F 46
10 SS F 45
11 SS F 47
12 SS F 45
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Tool Kit (GATK) algorithm; and (6) assigning quality 
scores to variants (detailed workflow information in the 
Additional file 1).
Subsequently, we included a filtering phase (using 
information from dbSNP and the 1K Exome Project), 
with the following sequential steps: (1) identification of 
novel variants i.e., those variants absent from the 1,000 
genomes and dbSNP databases (the 1,000 genomes—
phase 3—has a set of 95 individuals recruited from 
Colombia; the same area of ascertainment of these 
sporadic cases); (2) filtering of variants to include 
either pathogenic or specific variants associated to dis-
ease with numerous tools i.e., SIFT, PolyPhen2, Muta-
tion Taster, Mutation Assessor, and FATHMM (more 
detailed information in the Additional file 1) as imple-
mented in the DNA-seq Analysis Package SVS7.7.6, 
Golden Helix, Bozeman, USA [9]. Variants were not 
excluded if classified as potentially damaging by at least 
one of these filtering tools. These variants are not nec-
essarily non-synonymous, but can also include those 
found in splice sites or that are a part of splicing regula-
tory elements, as identified by the variant classification 
and Human Splice Finder algorithms respectively [9–
13]. (3) Filtering of damaging variants based on genes 
known to be associated with human disease; and (4) 
independent confirmation of selected variants by Sanger 
sequencing (detailed information in the Additional file 
1). The identification of likely compound heterozygous 
polymorphisms, and rare recessive homozygous poly-
morphisms, was performed with different modules of 
the DNA-seq Analysis Package in SVS7.7.6, Golden 
Helix, Bozeman, USA [9], in combination with custom 
Python scripts. For any homozygous intronic variants 
identified (in cases only) during the initial filtration pro-
cess, further analysis was conducted using algorithms 
of the Human Splice Finder [12], in order to identify 
possible motifs harbouring mutations that might have 
an effect on splicing regulation (splicing regulatory ele-
ments or SREs). In brief, position weight matrices are 
constructed for the predicted sequence motifs, in order 
to measure the level of nucleotide sequence conserva-
tion, as well as their enrichment in introns vs. exons 
[12]. Sequences that have more enriched matrix scores 
in a given intronic region compared to other locations 
in the gene’s exons and introns are considered as can-
didate splicing regulators [12]. Thus our approach is 
attempting to extract as much information as possible 
from non-synonymous and splicing variants as well as 
other non-coding variants proximal to exon boundaries, 
in order to reduce the risk of excluding genes that may 
have substantial importance in the phenotypes of these 
autoimmune patients.
Network analysis
To identify potential enriched MAS related physiological 
pathways, network analyses were performed. For con-
structing networks and pathways, variants with potential 
functional changes, detected as novel and in homozygote 
state, were examined with the ‘Analyse Network’, ‘Process 
Networks’, ‘Shortest Paths’ and ‘Direct Interactions’ algo-
rithms implemented within the MetaCore software suite 
(Version 6.2, Build 66481, Thomson Reuters, New York, 
USA) (details regarding some the differences between the 
algorithms can be found in the MetaCore Manual). These 
procedures allowed us to use a heuristic integration 
of maps and networks and rich ontologies for diseases 
based on the biological role of candidate genes.
The human gene connectome (HGC)
Similar to MetaCore, the rationale of implementing the 
HGC is also for prioritizing candidate genes on the basis 
of their functional relevance to autoimmune phenotypes. 
In this case however, candidate genes were chosen on the 
basis of their quantitative relatedness or biological dis-
tance to genes already established as having functional 
importance in ADs. This was used to calculate biological 
distances between candidate genes identified from the 
aforementioned filtering strategies and previously identi-
fied genes with potential functional relevance in autoim-
munity, including but not limited to rheumatoid arthritis 
(RA), SS, systemic lupus erythematous (SLE) and auto-
immune thyroid disease (AITD) [14–16]. The genes with 
known functional/physiological relevance and/or associa-
tion to autoimmunity were obtained from the Gene Pros-
pector database [16]. Genes within the top 10% listed for 
each disease and shared amongst multiple ADs of interest 
(present in the MAS patients) were selected for the HGC 
analysis of candidate genes (detailed information in the 
Additional file 1). To evaluate the significance of these dis-
tances, P values were estimated via random permutation 
of pairwise gene interactions in the HGC database. These 
values were subsequently corrected using the Benjamini 
and Hochsberg false discovery rate (FDR) method [17].
Principal component analysis
Population stratification and substructure can generate 
spurious association and consequently inaccurate conclu-
sions about the enrichment of candidate variants in cases 
over controls. Although our dataset contains exome-
sequencing variants from individuals who are from a 
homogeneous region, small levels of microdifferentiation 
may be present. We control this potential confounder by 
applying genotype based principal component analysis 
(PCA), as implemented in SVS 7.7.6, Golden Helix, Boze-
man, USA [9, 18] to identify outliers.
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Results
Identifying potential population structure
After applying PCA, there was no evidence of stratifica-
tion effect between cases and controls. No outliers from 
both groups were identifiable.
Candidate genetic variants identified from initial filtering 
procedures
The filtering strategies were essential tools in order to 
successfully obtain a refined, prioritized list of candidate 
genes, with potential importance in the MAS patients. 
Using the aforesaid approach, we successfully identi-
fied 11 variants within the following genes: DUSP12, 
GRIN3B, KIAA0754, MACF1, LRP1, STAT6, BABAM1, 
ANKLE1, TMEM161A, MICAL1, ICA1, FKRP and 
CELA1. The LRP1/STAT6 mutation compromise an exon 
that encodes these two genes that run in different senses. 
There was also one shared by KIAA0754 and MACF1 and 
another by BABAM1 and ANKLE1 (Table 2). Ten out of 
the 12 affected individuals had at least 1 homozygous or 
a pair of compound heterozygous variants within genes, 
which were not observed in the controls.
By definition, mutations in the CELA1 (chymotrypsin-
like elastase family, member 1) and TMEM161A (trans-
membrane protein 161A) genes were considered as splice 
mutations. This is because these variants are located 
within a GT-AG nucleotide portion of the intron along 
the DNA sequence that encodes the messenger RNA, 
which is evident after implementation of the integrative 
genomics viewer (IGV) [11, 19, 20]. It has been previously 
observed, that variants in these regions outside the exon 
boundary are well conserved in splice sites [11]. In addi-
tion, two heterozygous variants within the MACF1 
(microtubule-actin crosslinking factor 1) gene were pre-
sent in one of the four patients with SS. With the excep-
tion of the rare variants harboured in KIAA0754 and 
CELA1, each of these variants was absent from both: the 
dbSNP and the 1K databases. All of them had potentially 
deleterious effects according to at least one of the follow-
ing variant effect predictors: Polyphen, SIFT, FATHHM, 
MutationTaster and Mutation Assessor (Table 2).
Of particular importance was the DUSP12 (dual speci-
ficity phosphatase 12) gene; harbouring one homozygous 
novel mutation in a MAS patient affected by AITD, RA 
and SS, as well as a second heterozygous novel mutation 
in another MAS individual (diagnosed with Psoriasis, 
RA and SS). The LRP1 (low density lipoprotein receptor-
related protein 1) gene has one novel, non-synonymous 
mutation variants in two individuals. Both were affected 
with MAS. The heterozygote individual had AITD, SS 
and vitiligo, whilst the homozygote individual was diag-
nosed with AITD, RA and SS (Table  3). Interestingly, 
apart from non-synonymous and predicted splicing vari-
ants, 2 intronic single nucleotide polymorphisms (SNPs) 
within MICAL1 (microtubule associated monooxyge-
nase, calponin and LIM domain containing 1) and ICA1 
(islet cell autoantigen 1, 69  kDa) respectively were also 
identified as part of our list of candidate autoimmune 
causing mutations. Both of these variants are considered 
as ‘Disease Causing’ by the MutationTaster algorithm [21, 
Table 2 Candidate genetic variants identified amongst individuals carrying autoimmunity, which are absent from con-
trols
HGVS human genome variation society.
* Intronic; ** synonymous.
Chr Position Ref Allele Alt Allele Identifier Type of mutation Gene Transcript ID Exon HGVS protein
1 39,854,131 A C Unknown Nonsyn MACF1 NM_012090 52 p.Asn3144Thr
1 39,879,412 G A rs55976345 Nonsyn KIAA0754/MACF1 NM_015038 1 p.Ala1159Thr
6 109,767,639 G C Unknown Intronic/potential regulatory MICAL1 NM_001159291 * *
1 161,719,833 C G Unknown Nonsyn DUSP12 NM_007240 1 p.Pro81Arg
7 8,196,577 A T Unknown Intronic/potentially regulatory ICA1 NM_022307 * *
12 51,740,405 A G rs143199509 Splicing CELA1 NM_001971 1 Unknown
12 57,522,754 A C Unknown Nonsyn LRP1/STAT6 NM_002332 1 p.Thr3Pro
19 1,009,552 C G Unknown Nonsyn GRIN3B NM_138690 9 p.Ala1028Gly
19 17,392,775 C T Unknown Nonsyn BABAM1/ANKLE1 NM_001278444 1 p.Arg70Trp
19 17,392,775 C T Unknown Synonymous BABAM1/ANKLE1 NM_001278445 1 **
19 17,392,775 C T Unknown Nonsyn BABAM1/ANKLE1 NM_152363 1 p.Arg70Trp
19 19,245,591 A C Unknown Splicing TMEM161A NM_001256766 2 Unknown
19 19,245,591 A C Unknown Splicing TMEM161A NM_017814 2 Unknown
19 47,259,734 G C Unknown Nonsyn FKRP NM_001039885 4 p.Glu343Gln
19 47,259,734 G C Unknown Nonsyn FKRP NM_024301 4 p.Glu343Gln
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22]. After implementing IGV, it was found that the ICA1 
homozygous variant was located in an adenosine rich 
region, proximal to the 3′UTR of the mRNA sequence in 
one of the gene’s exons [19, 20]. In the case of MICAL1, 
the homozygous variant is 22  bp from the intron–exon 
boundary. In addition, it was also found that this variant 
is harboured within the vicinity of (i.e., <10  bp from) a 
sequence region containing 2 hexamer non-coding ele-
ments (also named as intron identity elements or IIE), 
which may act as splicing motifs, according to the algo-
rithms implemented in human splicing finder [12]. These 
motifs contain the following sequences: ATGGTG and 
TGGTGG [12, 13].
Quality evaluation of sequence reads
The information about mapping quality, which measures 
the confidence that a sequence read, corresponds to its 
aligned position in the genome, based on the strength 
of the alignment, and the Base Phred Score (a quantita-
tive estimate of the probability of an incorrect base call), 
reported a high quality of reads. In our case homozygous 
variants harboured in the DUSP12, ICA1 and LRP1/
STAT6 genes had a mapping quality of 42, greater than 
any other variant. In addition, the Phred Quality Scores 
for each of these genes was 34, 29 and 27 respectively 
(Additional file 1: Table  S1). This shows that for these 
variants, the probability of correct mapping during 
the alignment of these reads harbouring the variants is 
greater than 99.99%. Also, the likelihood of accurate base 
calls at each of these nucleotide positions is more than 
99.8%. Sanger sequencing was performed and confirmed 
the results (see Additional file 1).
Pathway and network analysis
Significant results from the ‘Analyze Network’ algorithm 
show that the alpha 2-macroglobulin receptor/low den-
sity lipoprotein receptor-related protein (alpha 2 MR/
LRP/A2M receptor, a large cell-surface glycoprotein 
(encoded by the LRP1 gene) is phosphorylated by pro-
tein kinase C-alpha (PKC alpha) during the following 
processes: phagocytosis, negative regulation of apoptosis 
and phospholipase A2 activity. According to MetaCore, 
these processes are also seemingly activated when Plas-
minogen Activator Urokinase Receptor (PLAUR) binds 
to the A2M receptor (Figure 1; Table 4). In addition, the 
application of the ‘shortest paths’ network algorithm, 
found that interferon (IFN) gamma interacts with the 
A2M receptor by regulating its transcription, which is 
important in response to lipopolysaccharides (Figure  2; 
Table  4). MICAL1 is another intriguing gene identified 
through network analyses. Like LRP1, MICAL1 is also 
involved in apoptosis regulation, actin filament depoly-
merisation, and negative regulation of cysteine type 
endopeptidase activity (Table  4). These functions occur 
as a result of network links shared by the PKC-mu and 
MICAL1 proteins (Figure 3). The extremely low P values 
of these aforementioned GeneGo processes associated 
to the nodes connected to LRP1 in both biological net-
works indicate that these functional associations do not 
occur by chance. Furthermore no other genes from these 
networks involving LRP1 and MICAL1 are functionally 
associated to these biological processes in the MetaCore 
database.
Human gene connectome output
The LRP1 gene has very short biological distances from 
the HLA-B, MBL2 and IL10 genes, as is the case with the 
distance between STAT6 and IRF5 (see Additional file 
1: Table S2; Additional file 1: Figure S1). The functional 
relatedness of LRP1 with HLA-B and IL10 is closer than 
most pairwise comparisons of core and candidate genes, 
used in this analysis. After FDR correction, the probabil-
ity of obtaining shorter distances after random permu-
tation and sampling of pairwise distance measurements 
for STAT6 and LRP1 against the remaining genes in the 
HGC database was <0.05 in all cases. The FDR corrected 
P values for these distances involving LRP1 were 0.02486, 
0.04428 and 0.04938 respectively. The distance measure-
ment for STAT6 and IRF5 yielded an adjusted P value of 
0.0388 (see Additional file 1: Table  S2). It must also be 
noted that STAT6 and ICA1 have already been identified 
Table 3 Phenotypes and genotypes of individuals carrying 
potentially genetic deleterious variants in autoimmunity, 
absent from controls
The chromosome and nucleotide position of the variant harboured within the 
candidate gene is given with the corresponding individuals, their phenotypes 
and the genotypes. See Table 1 for abbreviations.
Gene Variant Individual ID and  
phenotype
Genotype
MACF1 1:39,854,131 9 (SS) (AC)
MACF1/KIAA0754 1:39,879,412 9 (SS) (AG)
DUSP12 1:161,719,833 5 (AITD, RA, SS) (GG)
4 (PSO, RA, SS) (CG)
MICAL1 6:109,767,639 6 (AITD, RA, SS) (CC)
ICA1 7:8,196,577 12 (SS) (TT)
CELA1 12:51,740,405 6 (AITD, RA, SS) (GG)
LRP1/STAT6 12:57,522,754 1 (AITD, SS, VIT) (AC)
3 (AITD, RA, SS) (CC)
GRIN3B 19:1,009,552 4 (PSO, RA, SS) (GG)
BABAM1/ANKLE1 19:17,392,775 11 (SS) (TT)
TMEM161A 19:19,245,591 11 (SS) (CC)
2 (SS, SSc, AIH) (AC)
FKRP 19:47,259,734 11 (SS) (CC)
7 (SLE, SS, AITD) (CC)
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Table 4 Network and pathway analysis showing the most likely candidate genes with functional relevance in autoimmunity
The first P value is of the constructed network. This gives the probability of obtaining a certain number of genes obtained from a given network algorithm from the 
input list by random chance. Also given are the network nodes and their corresponding biological processes that may have functional importance in ADs.
Gene Network algorithm (P value) Network node GeneGO ontology process Processes P value
LRP1 Analyse network (3.03e−7) PKC alpha (phosphorylation of the A2M 
receptor encoded by LRP1) (Figure 1)
Phagocytosis 7.596e−8
LRP1 Analyse network (3.03e−7) PKC‑alpha (phosphorylation of the A2M 
receptor encoded by LRP1) (Figure 1)
Regulation of phospholipase A2 activity 3.597e−13
LRP1 Analyse network (3.03e−7) PKC‑alpha (phosphorylation of the A2M 
receptor encoded by LRP1) (Figure 1)
Negative regulation of apoptosis 6.703e−21
LRP1 Shortest paths (N/A) LRP1 (transcription regulation) IFN‑gamma 
(Figure 2)
Response to lipopolysaccharide 7.616e−21
MICAL1 Analyse network (7.32e−10) PKC‑mu MICAL1 (Figure 3) Negative regulation of apoptotic process 7.901e−15
MICAL1 Analyse network (7.32e−10) PKC‑mu MICAL1 (Figure 3) Actin filament depolymerisation 2.34e−2
MICAL1 Analyse network (7.32e−10) PKC‑mu MICAL1 (Figure 3) Negative regulation of cysteine type endo‑
peptidase activity
5.403e−3
Figure 1 Network analysis of candidate genes involving LRP1 and its potential role in autoimmunity. The network is showing the mechanisms 
by which protein kinase molecules activate the A2M receptor encoded by the LRP1 gene. The protein highlighted with a hexagonal yellow dot 
is formed from one of the genes that were identified from the preliminary filtration strategies and used as an input list for the network‑building 
algorithm (in this case gene was LRP1). The cellular locations (i.e., cytoplasm and extracellular membrane) of the interacting molecules, which in 
this case include protein kinases and the A2M receptor is given. Also included are the mechanisms by which one molecule interacts with another. P 
phosphorylation, B binding, GR group relation, TR transcriptional regulation. The effect of these mechanisms is denoted in the colour of the symbols 
corresponding to the respective nodes is as follows: pink activation (by phosphorylation), grey activation (by binding), blue activation (by transcrip‑
tional regulation), green unspecified effect due to group relation.
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as genes with established functional importance in SLE 
and SS respectively within the GeneProspector database 
[16]. MICAL1 is another gene, which had close related-
ness to important immune system genes such as PTPN22 
and TLR9, whilst DUSP12 had a significantly short dis-
tance to TSHR. However, these distances only had nomi-
nal significance. Even though the variant in MICAL1 is 
not within a coding region or splice site, it is still consid-
ered functionally relevant, according to the variant effect 
predictor and biological network analyses.
Discussion
As a whole, our strategy has been successful in identify-
ing candidate genetic variants that may account for pol-
yautoimmunity as well as for SS. One factor that must 
be acknowledged in this approach is the identification 
of compound heterozygotes for the MACF1 gene. Given 
that this gene spans 92 exons and more than 402 Kb [23], 
this increases the likelihood of identifying more than one 
heterozygote in a particular individual by chance (com-
pared to smaller genes), regardless of whether these vari-
ants are causative or not. On this basis, one can argue 
that such genes should be excluded, but at the same time, 
size alone cannot rule out the fact that these variants may 
be potentially causative. In this case, these variants were 
included, as part of our analysis. However their inclu-
sion or exclusion does not change our conclusions about 
which genes are the best candidates for observed MAS 
phenotypes.
Other studies involving correlated meta-analyses and 
factor analysis for inflammatory markers and metabolic 
traits have suggested that MACF1 and KIAA0754 con-
tained significant pleiotropic association with high den-
sity lipoprotein cholesterol and C-reactive protein levels. 
Consequently, this renders these genes as risk factors for 
metabolic syndrome, which may result in a genetic pre-
disposition for cardiovascular disease and diabetes [24]. 
Although no patients from our study were diagnosed 
with either condition those carrying the KIAA0754 and 
MACF1 may have an increased susceptibility to these dis-
orders [24].
Based on these comprehensive analyses we also found 
intriguing evidence that LRP1 and STAT6 have the strong-
est case for being categorised as potentially causative 
genes of MAS. This observation came along with: (1) the 
ascertainment of patients with extreme autoimmune phe-
notypes; (2) the recruitment from a population exhibiting 
features of a well-established homogeneous population; (3) 
the identification by whole exome capture and sequenc-
ing of novel (i.e., not present in dbSNP or 1,000 genomes 
Figure 2 Network analysis of candidate genes involving the A2M receptor intracellular domain. In this network, the effect of the A2M receptor 
(encoded by LRP1) intracellular domain upon IFN‑gamma is illustrated. Locations of relevant proteins in this network are shown in the nucleus, cyto‑
plasm and extracellular membrane respectively. The mechanistic nature of the protein interactions in the network are as follows: TR transcriptional 
regulation, B binding, P phosphorylation. The downstream effects exhibited by the protein–protein interactions between a given set of nodes are 
represented by the following colours on each of the mechanism symbols: green inhibition (by transcriptional regulation), grey activation (by bind‑
ing), pink activation (by phosphorylation). The A2M receptor and the STAT6 transcription factor are highlighted with a yellow dot, showing that they 
are part of the candidate gene list used as an input source for the network‑building algorithm implemented to generate this biological network.
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projects) and rare functional coding variants (some of 
them in at least two patients); and (4) the presence of 
intriguing patterns of functional correlations among them, 
or with other major genes shaping autoimmunity.
Undoubtedly, the association of LRP1 with the phe-
notypes of two MAS patients constitutes an interesting 
finding that validates the results of the present study. 
Indeed, several lines of evidence suggest that LRP1 prod-
uct is involved in crucial extracellular and intracellular 
anti-inflammatory pathways that play key roles in main-
taining the homeostasis of the immune system [25–29]. 
Therefore, a damaging mutation in this gene might 
largely contribute to the occurrence of MAS.
LRP1 is largely expressed in phagocytic cells such as 
peripheral macrophages and brain microglia that play 
crucial roles in engulfing cellular debris such as apop-
totic cell bodies, amyloid β peptide and chromatin [27, 
28, 30]. Remarkably, it has been previously described that 
reduced clearance of dying cells by macrophages causes 
accumulation of cellular fragments in several tissues [31, 
32]. This process appears to induce dendritic cells (DC), 
professional antigen presenting cells that activate naïve 
T-cells, to uptake apoptotic debris [31]. After that, DCs 
might present self-antigens to naïve T cells and activate 
autoreactive T cells [31]. Thus, impaired LRP1 action 
could ultimately cause autoimmunity.
The crucial anti-inflammatory role of LRP1 in coun-
teracting deleterious effects of neurodegenerative dis-
eases has been previously reported [25, 28]. For instance, 
decreased expression of LRP1 has been hypothesized to 
be crucial in the extracellular accumulation of beta amy-
loid protein occurring during Alzheimer’s disease [25]. 
Furthermore, LRP1 has also been hypothesized to play 
a crucial role in clearing apoptotic cells during multiple 
sclerosis [28]. In summary, the involvement of LRP1 in 
the removal of cellular debris might constitute a key step 
in preventing autoimmunity.
There are other lines of evidence suggesting that LRP1 
has anti-inflammatory roles, which indirectly could also 
aid in the prevention of autoimmunity. First, one of the 
key LRP1 ligands, alpha-2-macroglobulin (A2MG), 
enhances survival during sepsis through a novel mode 
of interaction between cells that involve plasma mem-
brane-shed vesicles containing large proteins and lipid 
mediators [29]. These vesicles are termed micropar-
ticles and one of their key components to prevent sep-
sis is A2MG, which acts through LRP1 [30]. Secondly, 
increased levels of glucocorticoids occurring during 
inflammatory challenges aimed at self-containing the 
inflammatory cascade also increase the expression of 
LRP1 in phagocytic cells such as macrophages, which 
contribute to the removal of apoptotic cells as described 
above [27]. Thirdly, there is an intracellular self-lim-
iting anti-inflammatory process that involves LRP1 
[26]. Recent in vitro studies described that proteolytic 
processing of the intracellular domain of the protein 
encoded by LRP1 triggered nuclear signalling to dampen 
the expression of key inflammatory LPS-induced genes 
such as interferon regulatory factor-3 (IRF-3) [29]. More 
specifically, it was shown that the soluble intracellular 
domain encoded by LRP1 translocates to the nucleus 
to repress the LPS-induced increase of IRF-3, a cru-
cial transcription factor that regulates the expression of 
other inflammatory genes.
The HGC and the MetaCore analyses provided addi-
tional evidence for LRP1 and STAT6 as potentially causal 
genes within these particular individuals from a func-
tional perspective. As mentioned earlier, IL10 is related 
to LPR1 and has an important role in immunological 
function acting as a negative regulator of the inflamma-
tion response [33]. Therefore, a mutation that disrupts 
this gene’s function would lead to a hyper inflammatory 
Figure 3 Network analysis illustrating the function of MICAL1 in 
autoimmune related processes. Of particular importance in the 
network is the interaction between protein kinase C mu and MICAL. 
The MICAL protein is highlighted with a circular yellow dot (as was the 
case for the A2M receptor in Figures 1 and 2) because it is encoded 
by the MICAL1 that was part of the user generated input list for the 
MetaCore network‑building algorithm. The mechanistic nature of the 
protein interactions in the network are as follows: P phosphorylation. 
The downstream effects exhibited by protein–protein interactions 
between a given set of nodes are represented by the following: pink 
activation by phosphorylation, grey phosphorylation with unspecified 
effect.
Page 9 of 11Johar et al. J Transl Med  (2015) 13:173 
response, which might account for the elevated IL-10 lev-
els in RA [33] and SS [34].
Based on the significance of the distance measure-
ments, the functional proximity between core and can-
didate genes on the cluster plot and the assumptions of 
the connectome analysis, LRP1 may have an important 
role in ADs such as RA, SS and AITD via similar mecha-
nisms, networks and/or pathways as IL10. Evidence for 
this interpretation is further enhanced by the fact that 
the individual homozygous for the LRP1 variant contains 
these precise phenotypes (i.e., RA, SS, AITD).
Although LRP1 has the strongest evidence as a candi-
date gene, MICAL1 also may have physiopathological 
relevance in ADs, as it has a close biological proxim-
ity to PTPN22, an autoimmune gene. A functional SNP 
C1858T in PTPN22 which alters the responsiveness of T 
and B cells is associated with some ADs in our popula-
tion including SS [35, 36].
In addition to the genes above, it is also clear that 
this approach identified well known genes associated 
with autoimmunity within the exome variant data of 
these patients, which in this case are ICA1 and STAT6 
(encoded by the same variant as LRP1). This suggests 
that the filtration strategies we applied have good valid-
ity and reliability in identifying potential MAS caus-
ing genes. The significantly short functional proximities 
of these genes is to be expected, given that ICA1 inter-
acts with AIRE in the production of self-antigen [37] 
and therefore has been functionally linked with SS [38]. 
The signal transducers and activators of transcription 
(STATs) including STAT6 are latent cytoplasmic proteins 
that undergo tyrosine phosphorylation by Janus kinases 
(JAKs) in response to cytokine exposure in the extracel-
lular milieu [39]. This involves phosphorylation of JAKs, 
which allows dimerization of STAT molecules, enabling 
transcriptional regulation of target genes. Transcriptional 
regulation by STAT6 occurs as a result of its capability 
to transform chromatin between open and closed states 
at target loci [39]. It should be stressed that the variants 
identified within ICA1 and MICAL1 are not categorised 
as coding or splice-site SNPs. However, this does not 
mean that these variants are not functionally relevant, 
because the ICA1 homozygous variant is seemingly part 
of a poly A tail, which is suggested through its sequence 
analysis via the use of the IGV [19, 20]. Another possi-
ble explanation is that the sequenced region has high 
levels of sequence conservation. Both of these explana-
tions may account for the assignment of this variant as 
‘Disease Causing’ by the Mutation Taster algorithm (see 
Additional file 1: Table S1). Conversely, the variant har-
boured in MICAL1 is located in a region that could be 
important in intron splicing regulatory element activity 
as mentioned earlier [12, 13]. This inference is not only 
based on the results from the Human Splice Finder 
(motif predictor) [12, 13]. Instead, empirical observations 
from previous studies have illustrated that intronic splic-
ing regulatory elements up to 150  bp from alternatively 
spliced exons are highly conserved compared to consti-
tutive exons [40]. Therefore, given that this sequence 
is 22  bp from the intron exon boundary of MICAL1, it 
may have high levels of conservation. Thus if this SNP is 
located in a highly conserved region, it makes sense as to 
why it is predicted as a functional variant, as it may have 
important regulatory mechanisms in splicing, based on 
the evidence obtained thus far [19–22].
It must also be noted that ICA1, coding for ICA69 
autoantigen, has been previously associated with Diabe-
tes mellitus type 1 (T1DM), based on cDNA expression 
analysis in islet cells [41], as well as being implicated in SS 
[42]. ICA1 maps to chromosome 7p22, a locus previously 
associated with SS in our population [43]. It has been 
observed in past investigations that mice heterozygous 
for ICA1 as well as those carrying mutations for ICA1 
and AIRE (thereby hindering thymic ICA69 expression), 
exhibited suboptimal negative selection of ICA69 reac-
tive T cells in the thymus. This can drive autoreactive T 
cell mediated destruction, as is the case with T1DM, and 
also cause impaired function of other organs expressing 
ICA69 (i.e., the thyroid, the salivary glands, the brain, the 
stomach), meaning that it can contribute to a potential 
mechanism in the pathogenesis of ADs. This will occur 
especially if the autoreactive T cells affect the target 
organ. Further verification of this proposed mechanism 
is evident through the fact that no islet destruction was 
observed in cells carrying the ICA69 wildtype [41, 42]. 
Hence this mutation may be important in the SS pheno-
type observed in the individual homozygous for ICA1. In 
addition, ICA69 autoantibodies have been reported in 
SS and may reflect the broad spectrum of autoimmune 
abnormalities in this condition [44].
Although SS and T1DM share several genetics factors, 
the coexistence of both diseases is uncommon [36]. On 
the other hand, patients with SS may be prone to develop 
early subclinical atherosclerosis and have an altered lipid 
profile with potential atherosclerotic risk [45]. Neverthe-
less, the role of dyslipidaemia in favouring organic arte-
rial wall damage in these patients appears to be marginal 
[45]. Thus, other mechanisms including genetics may 
play a key role in determining the acceleration of athero-
sclerosis in SS. Therefore, the identified variants in our 
research may not only be relevant for the observed phe-
notypes in the MAS and SS patients, but also other sub-
phenotypes that could develop in these individuals later 
on.
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Conclusion
The application of different databases and quality con-
trol for filtering purposes has ensured that identified and 
filtered variants have been corrected for batch effects 
as well as analysed by any relevant bioinformatics tools, 
not just in terms of population frequency, but also from 
a physiological perspective. Thus, based on our results, 
these genes (in particular LRP1) should be considered as 
strong candidates for conferring risk to autoimmunity. 
We cannot exclude that mutations whose pathways are 
not plausible for autoimmunity could be related to other 
phenotypes non clinically overt in our patients. Hope-
fully our findings can be supported by future analysis of 
multigenerational families segregating autoimmunity 
[46], and will help to decipher the common mechanisms 
of autoimmunity (i.e., the autoimmune tautology) [4, 6].
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